Seer, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Seer, Inc. is a biotechnology company that develops and commercializes innovative proteomics solutions designed to decode the biology of the proteome. Its core product is the Proteograph Product Suite, an integrated solution consisting of proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software that enables unbiased, deep, rapid, and scalable proteomic analysis across complex biological samples. The Proteograph platform provides high-throughput access to proteins and peptides, capturing molecular information including protein variants, and is marketed primarily for research use in academic institutions, life sciences, biopharmaceutical, and biotechnology sectors. Seer operates globally with a presence in the United States, China, Australia, Eastern Europe, Israel, Japan, and South Africa. Founded in 2017 and headquartered in Redwood City, California, Seer has positioned itself as a leader in transformative proteomics technology. Recent major developments include the launch of new product applications for the Proteograph XT workflow specifically tailored for cell lysis proteomics, unlocking deeper intracellular proteomics capabilities. The company has also significantly increased instrument shipments in 2025, nearly tripling shipments in the first nine months compared to all of 2024, reflecting strong market demand. Seer expanded its strategic partnership with Thermo Fisher Scientific to accelerate adoption of the Proteograph Product Suite and continues to foster collaborations with leading service providers to broaden access to unbiased, deep proteomics at scale. Financially, Seer reported approximately $300 million in cash and investments as of late 2024 and projects revenue growth of around 24% for 2025, driven by product innovation, user base expansion, and increasing large-cohort studies in proteomics research. Seer targets proteomics and genomics markets offering research tools for biological discovery and biomarker identification. Its Proteograph platform integrates consumables, instrumentation, and analytical software to support scalable proteomic workflows compatible with widely used laboratory instruments. Seer’s strategic focus on external validation, technological innovation, and collaborative partnerships underscores its commitment to advancing proteomics for scientific research advancement worldwide. This comprehensive approach to proteomics and recent advancements in product applications, strategic partnerships, and market expansion emphasize Seer’s evolving leadership in life sciences and biotechnology sectors. Headquartered in Redwood City, California, Seer operates primarily in the United States with international reach in key global biotech markets. The company went public in 2020 and continues to grow its footprint through technology commercialization and service alliances. The CEO is Omid Farokhzad, who leads the company in driving adoption of its Proteograph technology platform.
Radoff-JEC Group Calls on Seer, Inc.'s Board of Directors to Publicly Acknowledge That the Company Needs to Be Taken Private and Disclose Timeline for Evaluating Latest Acquisition Offers
Seer Q2 Earnings Call Highlights
Seer, Inc. (SEER) Q2 2026 Earnings Call Transcript
Seer Reports Second Quarter 2026 Financial Results and Reaffirms Full Year 2026 Outlook
Seer to Participate in the Canaccord Genuity 46th Annual Growth Conference
Seer to Report Second Quarter 2026 Financial Results on August 11, 2026
SEER Investors Have Opportunity to Join Seer, Inc. Fraud Investigation with SBS Law
SEER Investors Have Opportunity to Join Seer, Inc. Fraud Investigation with SBS Law
Seer Confirms Receipt of Further Revised Unsolicited Acquisition Proposals From Radoff-JEC Group and From Omid Farokhzad, M.D.
SEER Investors Have Opportunity to Join Seer, Inc. Fraud Investigation with SBS Law
Seer Stockholders Vote to Re-Elect All Seven of Seer's Director Nominees at 2026 Annual Meeting
Radoff-JEC Group Submits Further Improved Proposal to Acquire Seer, Inc.
Radoff-JEC Group Urges Seer Stockholders to Vote “FOR” All Three of its Independent, Highly Qualified Nominees on the WHITE Proxy Card TODAY
Radoff-JEC Group Announces That Glass Lewis Has Joined ISS in Supporting its Case for Change at Seer, Inc.
Seer Urges Stockholders to Vote “FOR” Seer's Highly Qualified Director Nominees on the BLUE Proxy Card TODAY
Special Committee of Seer's Board of Directors Unanimously Rejects Unsolicited Acquisition Proposal from Omid Farokhzad, M.D.
Radoff-JEC Group Announces ISS' Support of its Case for Change at Seer, Inc.
Seer Board of Directors Issues Letter to Shareholders Setting the Record Straight
The Radoff-JEC Group Issues Letter to Fellow Seer, Inc. Stockholders Correcting the Company's Blatant Rewriting of History
SEER Investors Have Opportunity to Join Seer, Inc. Fraud Investigation with the Schall Law Firm